2L9H
Oligomeric Structure of the Chemokine CCL5/RANTES from NMR, MS, and SAXS Data
Summary for 2L9H
Entry DOI | 10.2210/pdb2l9h/pdb |
Related | 1u4l |
NMR Information | BMRB: 17453 |
Descriptor | C-C motif chemokine 5 (1 entity in total) |
Functional Keywords | immune system, chemokine, oligomer |
Biological source | Homo sapiens (human) |
Cellular location | Secreted: P13501 |
Total number of polymer chains | 4 |
Total formula weight | 31448.04 |
Authors | Wang, X.,Watson, C.M.,Sharp, J.S.,Handel, T.M.,Prestegard, J.H. (deposition date: 2011-02-09, release date: 2011-06-22, Last modification date: 2024-11-27) |
Primary citation | Wang, X.,Watson, C.,Sharp, J.S.,Handel, T.M.,Prestegard, J.H. Oligomeric Structure of the Chemokine CCL5/RANTES from NMR, MS, and SAXS Data. Structure, 19:1138-1148, 2011 Cited by PubMed Abstract: CCL5 (RANTES) is a proinflammatory chemokine known to activate leukocytes through its receptor, CCR5. Although the monomeric form of CCL5 is sufficient to cause cell migration in vitro, CCL5's propensity for aggregation is essential for migration in vivo, T cell activation and apoptosis, and HIV entry into cells. However, there is currently no structural information on CCL5 oligomers larger than the canonical CC chemokine dimer. In this study the solution structure of a CCL5 oligomer was investigated using an integrated approach, including NMR residual dipolar couplings to determine allowed relative orientations of the component monomers, SAXS to restrict overall shape, and hydroxyl radical footprinting and NMR cross-saturation experiments to identify interface residues. The resulting model of the CCL5 oligomer provides a basis for explaining the disaggregating effect of E66 and E26 mutations and suggests mechanisms by which glycosaminoglycan binding may promote oligomer formation and facilitate cell migration in vivo. PubMed: 21827949DOI: 10.1016/j.str.2011.06.001 PDB entries with the same primary citation |
Experimental method | SOLUTION NMR SOLUTION SCATTERING |
Structure validation
Download full validation report
